Banco Bilbao Vizcaya Argentaria S.A. Grows Stock Position in Cigna Group $CI

Banco Bilbao Vizcaya Argentaria S.A. lifted its position in Cigna Group (NYSE:CI) by 142.5% during the second quarter, HoldingsChannel.com reports. The fund owned 30,048 shares of the health services provider’s stock after acquiring an additional 17,656 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Cigna Group were worth $9,927,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in CI. Financial Network Wealth Advisors LLC boosted its stake in Cigna Group by 26.8% during the 1st quarter. Financial Network Wealth Advisors LLC now owns 161 shares of the health services provider’s stock worth $53,000 after purchasing an additional 34 shares during the last quarter. Central Pacific Bank Trust Division lifted its stake in shares of Cigna Group by 1.0% in the second quarter. Central Pacific Bank Trust Division now owns 3,440 shares of the health services provider’s stock worth $1,137,000 after buying an additional 35 shares in the last quarter. HBK Sorce Advisory LLC boosted its position in Cigna Group by 3.1% during the second quarter. HBK Sorce Advisory LLC now owns 1,263 shares of the health services provider’s stock worth $418,000 after acquiring an additional 38 shares during the last quarter. Legacy Financial Advisors Inc. grew its stake in Cigna Group by 2.9% during the 1st quarter. Legacy Financial Advisors Inc. now owns 1,400 shares of the health services provider’s stock valued at $461,000 after acquiring an additional 39 shares in the last quarter. Finally, Samalin Investment Counsel LLC raised its holdings in Cigna Group by 2.2% in the 1st quarter. Samalin Investment Counsel LLC now owns 1,792 shares of the health services provider’s stock valued at $590,000 after acquiring an additional 39 shares during the last quarter. 86.99% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO David Cordani acquired 4,134 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was purchased at an average price of $241.88 per share, with a total value of $999,931.92. Following the transaction, the chief executive officer owned 157,935 shares of the company’s stock, valued at approximately $38,201,317.80. This trade represents a 2.69% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Brian C. Evanko sold 5,368 shares of the business’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $300.00, for a total value of $1,610,400.00. Following the completion of the sale, the insider directly owned 51,182 shares in the company, valued at approximately $15,354,600. The trade was a 9.49% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.70% of the company’s stock.

Analyst Ratings Changes

CI has been the topic of several recent research reports. Robert W. Baird set a $372.00 target price on Cigna Group in a report on Thursday, August 14th. Sanford C. Bernstein dropped their target price on Cigna Group from $346.00 to $294.00 and set a “market perform” rating for the company in a report on Wednesday. Wells Fargo & Company cut their target price on Cigna Group from $354.00 to $300.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 5th. Morgan Stanley reissued an “overweight” rating and set a $355.00 price target on shares of Cigna Group in a research report on Friday, October 31st. Finally, Wolfe Research dropped their price objective on shares of Cigna Group from $345.00 to $325.00 and set an “outperform” rating for the company in a report on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $334.05.

Cigna Group Price Performance

NYSE:CI opened at $269.52 on Friday. Cigna Group has a 52 week low of $239.51 and a 52 week high of $350.00. The stock’s fifty day moving average is $289.75 and its two-hundred day moving average is $301.38. The company has a market capitalization of $72.00 billion, a P/E ratio of 14.71, a P/E/G ratio of 0.88 and a beta of 0.44. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 0.65.

Cigna Group (NYSE:CI) last issued its quarterly earnings data on Thursday, October 30th. The health services provider reported $7.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.64 by $0.19. Cigna Group had a return on equity of 18.80% and a net margin of 1.92%.The firm had revenue of $69.57 billion during the quarter, compared to the consensus estimate of $66.40 billion. During the same period last year, the company earned $7.51 EPS. The company’s quarterly revenue was up 9.5% on a year-over-year basis. Cigna Group has set its FY 2025 guidance at 29.600- EPS. Equities analysts expect that Cigna Group will post 29.77 EPS for the current year.

Cigna Group Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Thursday, December 4th will be issued a $1.51 dividend. This represents a $6.04 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Thursday, December 4th. Cigna Group’s dividend payout ratio is currently 26.64%.

Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.